HALO - Halozyme Therapeutics EPS beats by $0.07 beats on revenue

Halozyme Therapeutics (NASDAQ:HALO): Non-GAAP EPS of $0.55 beats by $0.07; GAAP EPS of $1.48 beats by $1.06. Revenue of $115.83M beats by $9.99M. Press Release Guidance Revenues of $430 million to $445 million, increased from prior guidance of $425 million to $445 million, representing year-over-year growth of 61%-66%; Non-GAAP Diluted Earnings per Share of $1.90 to $2.00, compared to prior guidance of $1.85 to $2.00, representing year-over-year growth of 70%-79%. Consensus EPS Estimate for 2021 is $1.92. Consensus Revenue Estimate for 2021 is $438.38M.

For further details see:

Halozyme Therapeutics EPS beats by $0.07, beats on revenue